Perrigo wins tentative FDA approval for generic Prandin

Drug used to treat Type 2 diabetes

ALLEGAN, Mich. – The Food and Drug Administration has given tentative approval to a generic diabetes drug.

Perrigo Co. announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

Tentative approval means that the drug meets the basic conditions for FDA approval, but the agency must wait to grant final approval until patent-protection or market exclusivity periods have ended; in the case of Prandin, India-based Sun Pharmaceutical Industries won approval for a generic version of the drug and will have 180 days in which to compete exclusively with Novo Nordisk's product.

Prandin has annual sales of about $250 million, according to Symphony Health Solutions.

Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

Login or Register to post a comment.